ACADIA Pharmaceuticals Inc. (ACAD): Today's Featured Drugs Laggard

ACADIA Pharmaceuticals was a leading decliner within the drugs industry, falling $0.41 (-2.1%) to $18.63 on light volume
By TheStreet Wire ,

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

ACADIA Pharmaceuticals

(

ACAD

) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.2%. By the end of trading, ACADIA Pharmaceuticals fell $0.41 (-2.1%) to $18.63 on light volume. Throughout the day, 1,124,880 shares of ACADIA Pharmaceuticals exchanged hands as compared to its average daily volume of 3,426,700 shares. The stock ranged in price between $18.50-$19.06 after having opened the day at $18.94 as compared to the previous trading day's close of $19.04. Other companies within the Drugs industry that declined today were:

Mast Therapeutics

(

MSTX

), down 37.2%,

IntelliPharmaCeutics International

(

IPCI

), down 20.4%,

Pernix Therapeutics Holdings

(

PTX

), down 16.9% and

Abaxis

(

ABAX

), down 16.1%.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. ACADIA Pharmaceuticals has a market cap of $1.7 billion and is part of the health care sector. Shares are up 309.5% year to date as of the close of trading on Thursday. Currently there are 8 analysts that rate ACADIA Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates

ACADIA Pharmaceuticals

as a

sell

. Among the areas we feel are negative, one of the most important has been weak operating cash flow.

On the positive front,

Senesco Technologies

(

SNTI

), up 56.1%,

Gentium SpA

(

GENT

), up 49.7%,

GW Pharmaceuticals PLC ADR

(

GWPH

), up 24.7% and

Idera Pharmaceuticals

(

IDRA

), up 16.3% , were all gainers within the drugs industry with

Novo Nordisk A/S

(

NVO

) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

Loading ...